Profile data is unavailable for this security.
About the company
Pulmatrix, Inc. is a biopharmaceutical company. The Company is focused on the development of novel inhaled therapeutic products intended to prevent and treat migraine and respiratory diseases with unmet medical needs using its patented iSPERSE technology. The Company’s proprietary product pipeline includes treatments for central nervous system (CNS) disorders such as acute migraine and serious lung diseases such as Chronic Obstructive Pulmonary Disease (COPD) and allergic bronchopulmonary aspergillosis (ABPA). Pulmatrix’s product candidates are based on its proprietary engineered dry powder delivery platform, iSPERSE, which seeks to enhance therapeutic delivery to the lungs by optimizing pharmacokinetics and reducing systemic side effects to improve patient outcomes. iSPERSE is a proprietary technology that allows a broad range of drugs to be formulated as small, dense, and dispersible particles for efficient drug delivery and deep penetration into the lungs.
- Revenue in USD (TTM)3.00k
- Net income in USD-6.22m
- Incorporated2013
- Employees2.00
- LocationPulmatrix Inc945 CONCORD STREET, SUITE 1217FRAMINGHAM 01701United StatesUSA
- Phone+1 (781) 357-2333
- Fax+1 (302) 636-5454
- Websitehttps://www.pulmatrix.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Kiora Pharmaceuticals Inc | 0.00 | -8.54m | 7.87m | 12.00 | -- | 0.3279 | -- | -- | -2.05 | -2.05 | 0.00 | 6.53 | 0.00 | -- | -- | 0.00 | -24.99 | -48.77 | -27.44 | -56.18 | -- | -- | -- | -276.73 | -- | -- | 0.00 | -- | -- | 42.93 | 127.56 | -- | -- | -- |
| Curative Biotechnology Inc | 0.00 | -6.02m | 7.94m | 4.00 | -- | -- | -- | -- | -0.0105 | -0.0105 | 0.00 | -0.0018 | 0.00 | -- | -- | 0.00 | -339.98 | -- | -- | -- | -- | -- | -- | -- | -- | -5.51 | -- | -- | -- | -- | -302.92 | -- | -- | -- |
| Curanex Pharmaceuticals Inc | 0.00 | -1.30m | 8.02m | -- | -- | 0.5614 | -- | -- | -0.0497 | -0.0497 | 0.00 | 0.5043 | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -- | -142.76 | 0.00 | -- | -- | -- | -1,782.87 | -- | -- | -- |
| Biomx Inc | 0.00 | -37.38m | 8.59m | 52.00 | -- | -- | -- | -- | -30.62 | -30.62 | 0.00 | 7.43 | 0.00 | -- | -- | 0.00 | -86.77 | -48.34 | -103.85 | -57.24 | -- | -- | -- | -- | -- | -57.02 | 0.00 | -- | -- | -- | 32.26 | -- | -53.03 | -- |
| StimCell Enegetics Inc | 0.00 | -935.22k | 8.66m | 0.00 | -- | -- | -- | -- | -0.0461 | -0.0461 | 0.00 | -0.0738 | 0.00 | -- | -- | -- | -2,062.23 | -844.03 | -- | -- | -- | -- | -- | -18,037.46 | -- | -17.22 | -- | -- | -- | -- | -297.42 | -- | -- | -- |
| BioVie Inc | 0.00 | -17.48m | 8.68m | 13.00 | -- | 0.4501 | -- | -- | -5.13 | -5.13 | 0.00 | 2.55 | 0.00 | -- | -- | 0.00 | -72.35 | -260.69 | -79.73 | -454.45 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 45.73 | -- | -- | -- |
| Pulmatrix Inc | 3.00k | -6.22m | 8.69m | 2.00 | -- | 1.84 | -- | 2,897.48 | -1.70 | -1.70 | 0.0008 | 1.30 | 0.0004 | -- | -- | 1,500.00 | -75.43 | -42.08 | -79.47 | -49.93 | -- | -- | -207,333.30 | -210.36 | -- | -- | 0.00 | -- | 6.96 | -0.2644 | 32.31 | -- | 46.99 | -- |
| Ernexa Therapeutics Inc | 1.00k | -18.36m | 8.72m | 6.00 | -- | 0.6644 | -- | 8,716.65 | -5.32 | -5.32 | 0.0002 | 0.4548 | 0.0001 | -- | 0.0059 | 166.67 | -264.07 | -187.10 | -2,044.59 | -237.72 | 100.00 | -- | -1,834,000.00 | -3,375.91 | -- | -2.73 | 0.00 | -- | 755.88 | -50.61 | -105.47 | -- | -19.54 | -- |
| Edesa Biotech Inc | 0.00 | -7.19m | 8.92m | 17.00 | -- | 2.39 | -- | -- | -1.35 | -1.35 | 0.00 | 1.74 | 0.00 | -- | -- | 0.00 | -82.86 | -103.16 | -99.57 | -123.95 | -- | -- | -- | -- | -- | -138.68 | 0.00 | -- | -- | -- | -16.46 | -- | -- | -- |
| Transcode Therapeutics Inc | 0.00 | -27.16m | 9.22m | 7.00 | -- | 5.88 | -- | -- | -354.09 | -354.09 | 0.00 | 1.71 | 0.00 | -- | -- | 0.00 | -592.26 | -153.21 | -1,387.56 | -219.22 | -- | -- | -- | -- | -- | -- | 0.00 | -- | -- | -- | 9.49 | -- | -- | -- |
| Bolt Biotherapeutics Inc | 5.20m | -42.68m | 9.60m | 52.00 | -- | 0.299 | -- | 1.85 | -22.27 | -22.27 | 2.71 | 16.72 | 0.0596 | -- | -- | 99,903.84 | -48.95 | -46.54 | -58.33 | -52.20 | -- | -- | -821.58 | -1,666.52 | -- | -- | 0.00 | -- | -2.36 | 104.50 | 8.79 | -- | -39.55 | -- |
| Holder | Shares | % Held |
|---|---|---|
| Renaissance Technologies LLCas of 30 Sep 2025 | 114.39k | 3.13% |
| BlackRock Fund Advisorsas of 30 Sep 2025 | 55.34k | 1.52% |
| SBI Securities Co., Ltd.as of 31 Dec 2025 | 55.24k | 1.51% |
| Geode Capital Management LLCas of 30 Sep 2025 | 40.94k | 1.12% |
| The Vanguard Group, Inc.as of 31 Dec 2025 | 32.29k | 0.88% |
| Vanguard Fiduciary Trust Co.as of 31 Dec 2025 | 14.79k | 0.41% |
| SSgA Funds Management, Inc.as of 30 Sep 2025 | 13.95k | 0.38% |
| Dimensional Fund Advisors LPas of 30 Sep 2025 | 10.78k | 0.30% |
| Tower Research Capital LLCas of 30 Sep 2025 | 1.44k | 0.04% |
| Flagship Harbor Advisors LLCas of 31 Dec 2025 | 80.00 | 0.00% |
